Analytical strategies for assessment of human metabolites in preclinical safety testing.
Strategies for the detection, identification, and quantification of in vivo drug metabolites from non-radiolabeled studies are reviewed with an emphasis on the utilization of accurate-mass-based data mining tools. New approaches to the determination of coverage of human drug metabolites in preclinical species without using radiolabeled drugs or synthetic standards are also discussed.